With 880 licenced innovations and 110 spin-outs, Yissum is the commercialisation front-runner

The changing role of HEIs globally is challenging universities to translate their research efforts into innovation and marketable technologies. The efficiency, productivity, and success of such processes, however, largely depends on a complex number of interconnected factors. These factors include the quality and skill set of the staff, the product-market fit, and possessing sufficient financial resources to support transfer activities. However, for those institutions who manage to solve this intricate equation there can be a high pay-off and the establishment a sustainable loop of innovation.

Since 1964, Yissum, the research development company of the Hebrew University of Jerusalem (HIJU), has been one of the key dominators in the tech transfer game. Yissum’s world renowned inventions have been making an impact on human lives across the world much longer than we realize: from the cherry tomatoes on your grocery list to the automated on-board driver assistant system ‘MobileEye’ in your car as well as the FDA Approved treatment medications: for ovarian cancer ‘Doxil’, chemotherapy ‘Erbitux’, and Alzheimer’s disease ‘Exelon’.

Yissum not only has helped its researchers to start more than 110 spin-off companies, of which some are currently valued over $10b on the stock exchange, but also facilitated the registration of 9,300 patents that cover more than 2,600 inventions, and licensed 880 innovations. Not surprisingly, this exceptional track record has attracted the attention of a number of industry giants, including Intel, Google, Philips, Coca Cola, Roche, GM, and P&G, for the establishment of long term research collaborations.

Want to learn more about the story behind Yissum’s breakthrough technologies? Read the detailed case study at: http://ub-cooperation.eu/index/casestudies